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risk in speciﬁc cytogenetic subgroups, to offer more guidance
to the practicing clinician. Our hope is that this and other
retrospective studies of MRD monitoring leads to an assess-
ment of the prognostic impact of MRD in well-deﬁned
molecular and cytogenetic subsets of AML. More importantly,
whether the presence of MRD should inﬂuence clinical
decision making needs to be investigated as a part of well-
designed prospective, randomized clinical trials.
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peptides (MAPs) displayed at the cell surface deﬁne our
immune self [1]. Under normal circumstances, MAPs pre-
sented by MHC class I and II molecules originate from
proteolytic degradation of self proteins. Importantly, some
MAPs are polymorphic; they are present in some persons,
but in other MHC-matched subjects they are absent or
present a slightly different amino acid sequence. For histor-
ical reasons, these polymorphic MAPs are referred to as
minor histocompatibility antigens (MiHAs). They are
a consequence of any form of accumulated genetic variation
that hinders MAP generation (eg, gene deletion) or the
structure of a MAP (eg, single nucleotide polymorphisms)
[2-4]. Thus, MiHAs are essentially genetic polymorphisms
viewed from a T cell perspective.
It is well known that after allogeneic hematopoietic cell
transplantation (AHCT), T cell responses against MiHAs
elicit graft-versus-host disease (GVHD) and graft-versus-
leukemia (GVL) response [5-8]. However, our understanding
of humanMiHA biology is based on scant molecular data and
therefore remains quite rudimentary. First, only a few MHC
IeassociatedMiHAs present on hematopoietic cells (typically
lymphoblastoid cell lines) have been well characterized in
humans, and we know practically nothing on MHC
IIeassociatedMiHAs andMiHAs speciﬁc tononhematopoietic
cells. Second,westill ignorehowmanydifferentMiHAs canberecognized by donor T cells on host cells after AHCT. In this
issue of Biology of Blood and Marrow Transplantation, Hobo
et al. report on the correlation between speciﬁc MiHA
disparities and AHCT outcome [9]. They performed genotyp-
ing for 17 MHC class Ieassociated MiHAs in a cohort of 327
AHCT donors and recipients and searched forMiHA-speciﬁc T
cells inpost-AHCTrecipients’blood samples. Then, theyasked
whetherMiHAdisparity and immunogenicity correlatedwith
recipients’ survival and relapse rate.
The ﬁrst conclusion reached by Hobo et al. is that
mismatch for autosomal MiHAs has no inﬂuence on the risk
of GVHD. This observation could be explained by two non-
mutually exclusive hypotheses. First, many of the MHC
Ieassociated MiHAs tested in this study were found only on
hematopoietic cells and therefore cannot trigger GVHD
because CD8 T cells require cognate interactions with target
(non hematopoietic) tissues to mediate GVHD [10]. Second,
the number of MHC Ie and MHC IIeassociated MiHAs
capable of triggering GVHDmay be so high that the impact of
a couple of MiHA disparities is negligible [2,4,11]. As
a corollary, it would be futile to try to decrease the risk of
GVHD by searching for MiHA-compatible donors. In view of
conclusion 1, it might appear surprising that mismatch for
so-called HY MiHAs correlated with a higher incidence of
acute GVHD. A plausible explanation is that HYmismatch has
a much greater signiﬁcance than an autosomal MiHA
mismatch. A disparity for 1 of the 14 autosomal MiHAs tested
means a single nucleotide variation that translates in
a mismatch for one single MHC Ieassociated peptide. In
contrast, an HY disparity means that the (female) donor and
the (male) recipient differ by 86 genes (on the Y chromo-
some) that can encode both MHC Ie and MHC IIeassociated
MiHAs [12]. Furthermore, HY MiHAs are ubiquitously
expressed. Hence, an HY mismatch implies a disparity for
a group of MiHAs present on both hematopoietic and non-
hematopoietic cells.
Interestingly, even though their patients presented
heterogeneous hematologic malignancies, data reported by
Hobo et al. suggest that mismatch for autosomal MiHAs is
C. Perreault / Biol Blood Marrow Transplant 19 (2013) 170e172172associated with a decreased relapse rate, in particular in
patients with multiple myeloma. This idea is consistent with
evidence that T cells speciﬁc for a single MiHA are sufﬁcient
to mediate a strong GVL response [7,13]. That a single MiHA
disparity may inﬂuence the strength of the GVL response also
suggests that, in contrast to GVHD, the GVL activity is
dependent on T cells speciﬁc for a limited number of hema-
topoietic MiHAs. More importantly, the report by Hobo et al.
should provide further impetus to efforts aimed at discov-
ering immunodominant MiHAs capable of mediating strong
GVL responses and at developing next-generation MiHA-
targeted cell therapies [8,14].
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